CYAD - Celyad phase 1b colorectal cancer trial put on hold by FDA citing safety after 2 deaths

The U.S. Food and Drug Administration placed a clinical hold on Celyad Oncology's (NASDAQ:CYAD) phase 1b trial, dubbed CYAD-101-002 (KEYNOTE-B79), due to insufficient information to assess risk to study patients. On Feb. 28, Celyad said it had voluntarily paused the phase 1b study (NCT04991948) — which is part of a collaboration with Merck & Co. (NYSE:MRK) — in colorectal cancer to investigate reports of two fatalities in the study. Celyad was evaluating its investigational drug CYAD-101 administered concurrently with FOLFOX chemotherapy, followed by Merck's Keytruda (pembrolizumab), in patients with refractory metastatic colorectal cancer. CYAD -0.88% premarket to $2.26

For further details see:

Celyad phase 1b colorectal cancer trial put on hold by FDA citing safety after 2 deaths